{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:01:04Z","timestamp":1755219664452,"version":"3.43.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102338","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T17:10:08Z","timestamp":1742922608000},"page":"102338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-3198","authenticated-orcid":false,"given":"Sergio","family":"V\u00e1zquez-Est\u00e9vez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Fern\u00e1ndez-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Juan-Fita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Montesa-Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urbano","family":"Anido-Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2025.102338_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"10024","key":"10.1016\/j.clgc.2025.102338_bib0002","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102338_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102338_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0007","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with Enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0009","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102338_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.clgc.2025.102338_bib0011","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"0","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0012","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102338_bib0013","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102096","article-title":"Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm","volume":"22","author":"Paolieri","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102338_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102171","article-title":"Treatment intensification with novel hormonal therapy in castration-sensitive prostate cancer: patient identification and clinical rationale","volume":"22","author":"Sternberg","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102338_bib0016","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/curroncol30040332","article-title":"Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)-A potential new standard of care","volume":"30","author":"Mittal","year":"2023","journal-title":"Curr Oncol"},{"issue":"37","key":"10.1016\/j.clgc.2025.102338_bib0017","first-page":"622","article-title":"The treatment of metastatic, hormone-sensitive prostatic carcinoma","volume":"119","author":"Merseburger","year":"2022","journal-title":"Dtsch Arztebl Int"},{"issue":"12","key":"10.1016\/j.clgc.2025.102338_bib0018","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"unstructured":"EMA. Nubeqa (darolutamide) SmPC. Accessed November 25, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf.","key":"10.1016\/j.clgc.2025.102338_bib0019"},{"unstructured":"FDA. Nubeqa (darolutamide). Prescribing information. Accessed 25 November 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212099s002lbl.pdf.","key":"10.1016\/j.clgc.2025.102338_bib0020"},{"issue":"15","key":"10.1016\/j.clgc.2025.102338_bib0021","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"9747","key":"10.1016\/j.clgc.2025.102338_bib0022","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clgc.2025.102338_bib0023","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.clgc.2025.102338_bib0024","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102338_bib0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0026","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"361","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0027","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Prostate Cancer Version 4.2024 \u2014 May 17, 2024 Accessed November 25, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1459, 2024.","key":"10.1016\/j.clgc.2025.102338_bib0028"},{"key":"10.1016\/j.clgc.2025.102338_bib0029","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0031","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0032","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102338_bib0033","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0034","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2025.102338_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0036","first-page":"265","article-title":"PARP inhibitors: the cornerstone of DNA repair-targeted therapies","volume":"31","author":"del Rivero","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clgc.2025.102338_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102338_bib0038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clgc.2023.12.011","article-title":"PARP Inhibitors in metastatic prostate cancer: A comprehensive systematic review and meta-analysis of existing evidence","volume":"22","author":"Ditonno","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102338_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104609","article-title":"Efficacy and safety of PARP inhibitors in prostate cancer: an umbrella review of systematic reviews and meta-analyses","volume":"207","author":"Tzang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102338_bib0040","article-title":"Recent and future developments in the use of poly (ADP-ribose) polymerase inhibitors for prostate cancer","author":"Zacchi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: A living interactive systematic review and meta-analysis","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.clgc.2025.102338_bib0042","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0043","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2025.102338_bib0044","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0046","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0047","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"unstructured":"FDA. Rubraca (rucaparib) SmPC. Accessed November 25, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209115s004lbl.pdf, 2020.","key":"10.1016\/j.clgc.2025.102338_bib0048"},{"key":"10.1016\/j.clgc.2025.102338_bib0049","doi-asserted-by":"crossref","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced ``BRCAness'' and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.clgc.2025.102338_bib0050","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.clgc.2025.102338_bib0051","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0052","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0053","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0054","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.clgc.2025.102338_bib0055","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2025.102338_bib0057","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0058","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0059","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0060","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0061","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102338_bib0062","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0063","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"6349","key":"10.1016\/j.clgc.2025.102338_bib0064","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clgc.2025.102338_bib0065","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0066","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102338_bib0067","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/annonc\/mdp308","article-title":"Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials","volume":"21","author":"Regan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0068","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102338_bib0069","doi-asserted-by":"crossref","first-page":"TPS297","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS297","article-title":"Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: open-label single-arm study with an external control arm (ARASEC)","volume":"41","author":"Shore","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euo.2022.07.001","article-title":"Double or triple trouble in metastatic hormone-sensitive prostate cancer?","volume":"5","author":"Kostos","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0071","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102338_bib0072","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102338_bib0073","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102338_bib0074","doi-asserted-by":"crossref","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.clgc.2025.102338_bib0075","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2022-CT007","article-title":"Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2025.102338_bib0076","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.clgc.2025.102338_bib0077","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2025.102338_bib0078","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102338_bib0079","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102338_bib0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/annonc\/mdw156","article-title":"Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review","volume":"27","author":"Hager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0081","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.3390\/cancers15153969","article-title":"Current trends in chemotherapy in the treatment of metastatic prostate cancer","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102338_bib0082","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-030-32656-2_13","article-title":"The role of RB in prostate cancer progression","volume":"1210","author":"Burkhart","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clgc.2025.102338_bib0083","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A randomized Phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2025.102338_bib0084","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2741\/4193","article-title":"Antibody-drug conjugates targeting prostate-specific membrane antigen","volume":"19","author":"Olson","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.clgc.2025.102338_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers14030503","article-title":"Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer","volume":"14","author":"Perera","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102338_bib0086","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","article-title":"Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial","volume":"103","author":"James","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102338_bib0087","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102338_bib0088","doi-asserted-by":"crossref","first-page":"E415","DOI":"10.5489\/cuaj.5154","article-title":"Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: expert opinion and review of the evidence","volume":"12","author":"Saad","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2025.102338_bib0089","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102338_bib0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pros.23492","article-title":"The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study","volume":"78","author":"Shou","year":"2018","journal-title":"Prostate"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:24:45Z","timestamp":1754551485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000394"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102338","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102338"}}